Capability
OxVax: Pioneering Off‑the‑Shelf Dendritic Cell Vaccines
How does OxVax's off-the-shelf dendritic-cell vaccine platform (CD141+ cells from iPSC) enable bulk immunotherapy manufacture?
OxVax Ltd is an Oxford-based immuno-oncology spin-off developing an off-the-shelf cancer vaccine. Defence-finance analysis; 39-page sourced DFM PDF report.
Full figures, sources and the complete assessment are in the report — Read the full DFM Analysis →
Part of our Research, Universities & Deep Tech and Defence & Dual-Use Companies coverage →
Original DFM publication · DFM Analysis report · 2025-08-18
OxVax Ltd is an Oxford-based immuno-oncology spin-off developing an off-the-shelf cancer vaccine platform built on a proprietary subset of dendritic cells.
This emerging biotech venture has its roots in the University of Oxford’s Sir William Dunn School of Pathology, where its founding scientists discovered how to generate CD141⁺ dendritic cells from induced pluripotent stem cells (iPSC) – a breakthrough enabling bulk manufacture of potent antigen-presenting cells for immunotherapy.
This analysis answers: How does OxVax's off-the-shelf dendritic-cell vaccine platform (CD141+ cells from iPSC) enable bulk immunotherapy manufacture? What is the maturity of this University of Oxford (Dunn School) spin-off's technology? Which immuno-oncology partners, markets and dual-use health-security applications does OxVax target? What capability gaps or dependencies affect scaling its proprietary dendritic-cell manufacturing?
Continue with the full evidence
This public thread is the short analytical version. The full DFM Analysis report adds the underlying figures and data, the complete source base, and the full procurement & capital-market assessment behind this summary.
Need the full document as a standalone file? Buy the full report (PDF) — €499
Annual Professional unlocks the complete archive and DFM Intelligence (2,200+ company profiles) — See plans →
Original DFM analysis
OxVax: Pioneering Off‑the‑Shelf Dendritic Cell Vaccines
FAQ
What is OxVax: Pioneering Off‑the‑Shelf Dendritic Cell Vaccines?
This emerging biotech venture has its roots in the University of Oxford’s Sir William Dunn School of Pathology, where its founding scientists discovered how to generate CD141⁺ dendritic cells from induced pluripotent…
Related DFM Platform threads
- Protected Satellite Communications (Operational Priorities) Capability
- Comand AI: AI-Driven Command-and-Control and Operational Planning Capability
- Kongsberg Ferrotech: Subsea Robotics for Europe’s Critical Infrastructure Security Capability
- Microamp Solutions: Enabling Secure 5G and mmWave Technologies for European Defence and Strategic Autonomy Capability
- Sensnet Analytics: European Fiber-Optic Sensing for Critical Infrastructure Security Capability
- Mynaric: Laser Communication Terminals for Secure Space Networks Capability
Explore this category Strategic Autonomy
Professional requests (internal interest signal — not a marketplace; nothing is charged or promised)
See Professional & Institutional Access — plans, group/institutional seats and contact →
Defence Finance Monitor is an analytical and informational product. It does not constitute investment advice, financial advice or a recommendation to buy or sell securities. Subscriptions run on DFM Analysis. Payments for Professional Packs are processed securely by Stripe at checkout.
Professional comments
Join the discussion on DFM Analysis.
Read & subscribe on DFM Analysis →